Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma
The objective of this study was to compare the efficacy and safety of the second controller medications (long-acting β2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler corticosteroid treatment in moderate persistent asthma. A total of 64 patie...
Gespeichert in:
| Veröffentlicht in: | Respiratory medicine 2002-05, Vol.96 (5), p.322-329 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 329 |
|---|---|
| container_issue | 5 |
| container_start_page | 322 |
| container_title | Respiratory medicine |
| container_volume | 96 |
| creator | YURDAKUL, A.S. ÇALIŞIR, H.C. TUNÇTAN, B. Ö Ǧ, M. |
| description | The objective of this study was to compare the efficacy and safety of the second controller medications (long-acting β2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler corticosteroid treatment in moderate persistent asthma. A total of 64 patients with asthma, in the moderate persistent asthma category, were divided into three groups. Patients, all of whom were concurrently using inhaled corticosteroid (Budesonide 400 μ g twice daily), were treated for 3 months with either inhaled formoterol 9 μ g twice daily (first group), oral zafirlukast 20 mg twice daily (second group), or sustained-release theophylline 400 mg once daily (third group). All of the patients were subjected to assessments on the subject of peak expiratory flow (PEF) variability, forced expiratory volume in 1 sec (FEV1), asthma symptom scores (daytime and night-time), supplemental terbutalin use, asthma exacerbations and adverse events over the 3-month treatment period. In all of the three groups, significant improvements were recorded in the lung function, asthma symptom scores and supplemental terbutalin use criteria, as a result of treatments applied. Formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria: PEF variability (17·9±2·5; 21·9±3·2; 23·7±3·3;P |
| doi_str_mv | 10.1053/rmed.2002.1282 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71882221</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0954611102912825</els_id><sourcerecordid>71882221</sourcerecordid><originalsourceid>FETCH-LOGICAL-c410t-ff2da0ca506d9592d0ff0cfca396e94f868620dc60ae215562c8bf8a0cacf51e3</originalsourceid><addsrcrecordid>eNp1kMFvFCEUh4nR2LV67dFwsbdZHzAzZY7NRqtJk17qmbzCI0szM6zA1vjfC9mNnrxAXvh-v0c-xq4EbAUM6nNayG0lgNwKqeUrthGDkp2CsX_NNjANfTcKIS7Yu5yfAWDqe3jLLoQUQiktNyzt4nLAFHJcefQ8k42r4_UoKc4zJV77g8US4pp5WDk6F9rAS6zjHmdqdCrBxlwoxeAadagBWkvmv0LZ8yU6SliIYy77Bd-zNx7nTB_O9yX78fXL4-5bd_9w9313e9_ZXkDpvJcOweIAo5uGSTrwHqy3qKaRpt7rUY8SnB0BSYphGKXVT163iPWDIHXJrk-9hxR_HikXs4RsaZ5xpXjM5kZoLaUUFdyeQJtizom8OaSwYPptBJhm2TTLplk2zXINfDw3H5_ay1_8rLUCn84AZouzT7jakP9x6kYJ2bfN-sRR9fASKJlsqzhbnSeyxbgY_veHP9iQm6Y</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>71882221</pqid></control><display><type>article</type><title>Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>YURDAKUL, A.S. ; ÇALIŞIR, H.C. ; TUNÇTAN, B. ; Ö Ǧ, M.</creator><creatorcontrib>YURDAKUL, A.S. ; ÇALIŞIR, H.C. ; TUNÇTAN, B. ; Ö Ǧ, M.</creatorcontrib><description>The objective of this study was to compare the efficacy and safety of the second controller medications (long-acting β2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler corticosteroid treatment in moderate persistent asthma. A total of 64 patients with asthma, in the moderate persistent asthma category, were divided into three groups. Patients, all of whom were concurrently using inhaled corticosteroid (Budesonide 400 μ g twice daily), were treated for 3 months with either inhaled formoterol 9 μ g twice daily (first group), oral zafirlukast 20 mg twice daily (second group), or sustained-release theophylline 400 mg once daily (third group). All of the patients were subjected to assessments on the subject of peak expiratory flow (PEF) variability, forced expiratory volume in 1 sec (FEV1), asthma symptom scores (daytime and night-time), supplemental terbutalin use, asthma exacerbations and adverse events over the 3-month treatment period. In all of the three groups, significant improvements were recorded in the lung function, asthma symptom scores and supplemental terbutalin use criteria, as a result of treatments applied. Formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria: PEF variability (17·9±2·5; 21·9±3·2; 23·7±3·3;P <0·001); asthma symptom score (daytime) (1·6±0·5; 1·9±0·5; 2·0±0,5; P<0·05); asthma symptom score (night-time) (1·2±0·4; 2·2±0·5; 1·8±0·6; P<0·001); and supplemental terbutalin use (1·2±0·3; 1·8±0·5; 1·7±0·5; P<0·05). However, at the end of the treatment, in all of the three groups studied, improvements were attained in overall asthma control and there was no statistical difference among the groups. Although there were no side effects which required the discontinuation of the treatment, it was observed that the maximum side effect was in the second group (20%, 31·6% and 20%, respectively). In conclusion, in patients who still have symptoms on treatment with inhaled corticosteroids, the addition of a long-acting β2-agonist, leukotriene antagonists or sustained-release theophylline to the treatment is a logical approach, and, in addition to inhaled corticosteroids, any one of these second controller medications may be chosen in patients with moderate asthma.</description><identifier>ISSN: 0954-6111</identifier><identifier>EISSN: 1532-3064</identifier><identifier>DOI: 10.1053/rmed.2002.1282</identifier><identifier>PMID: 12113382</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Adrenergic beta-Agonists - therapeutic use ; Adult ; Anti-Asthmatic Agents - adverse effects ; Anti-Asthmatic Agents - therapeutic use ; Asthma - drug therapy ; Asthma - physiopathology ; asthma, formoterol ; Biological and medical sciences ; Bronchodilator Agents - therapeutic use ; Budesonide - therapeutic use ; Chronic obstructive pulmonary disease, asthma ; Drug Therapy, Combination ; Ethanolamines - therapeutic use ; Female ; Formoterol Fumarate ; Glucocorticoids - therapeutic use ; Humans ; Leukotriene Antagonists - therapeutic use ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Phosphodiesterase Inhibitors - therapeutic use ; Pneumology ; Respiratory Mechanics - drug effects ; Respiratory system ; Theophylline ; Tosyl Compounds - therapeutic use ; treatment ; Tropical medicine ; zafirlukast</subject><ispartof>Respiratory medicine, 2002-05, Vol.96 (5), p.322-329</ispartof><rights>2002 Elsevier Science Ltd</rights><rights>2002 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c410t-ff2da0ca506d9592d0ff0cfca396e94f868620dc60ae215562c8bf8a0cacf51e3</citedby><cites>FETCH-LOGICAL-c410t-ff2da0ca506d9592d0ff0cfca396e94f868620dc60ae215562c8bf8a0cacf51e3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0954611102912825$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13731241$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12113382$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>YURDAKUL, A.S.</creatorcontrib><creatorcontrib>ÇALIŞIR, H.C.</creatorcontrib><creatorcontrib>TUNÇTAN, B.</creatorcontrib><creatorcontrib>Ö Ǧ, M.</creatorcontrib><title>Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma</title><title>Respiratory medicine</title><addtitle>Respir Med</addtitle><description>The objective of this study was to compare the efficacy and safety of the second controller medications (long-acting β2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler corticosteroid treatment in moderate persistent asthma. A total of 64 patients with asthma, in the moderate persistent asthma category, were divided into three groups. Patients, all of whom were concurrently using inhaled corticosteroid (Budesonide 400 μ g twice daily), were treated for 3 months with either inhaled formoterol 9 μ g twice daily (first group), oral zafirlukast 20 mg twice daily (second group), or sustained-release theophylline 400 mg once daily (third group). All of the patients were subjected to assessments on the subject of peak expiratory flow (PEF) variability, forced expiratory volume in 1 sec (FEV1), asthma symptom scores (daytime and night-time), supplemental terbutalin use, asthma exacerbations and adverse events over the 3-month treatment period. In all of the three groups, significant improvements were recorded in the lung function, asthma symptom scores and supplemental terbutalin use criteria, as a result of treatments applied. Formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria: PEF variability (17·9±2·5; 21·9±3·2; 23·7±3·3;P <0·001); asthma symptom score (daytime) (1·6±0·5; 1·9±0·5; 2·0±0,5; P<0·05); asthma symptom score (night-time) (1·2±0·4; 2·2±0·5; 1·8±0·6; P<0·001); and supplemental terbutalin use (1·2±0·3; 1·8±0·5; 1·7±0·5; P<0·05). However, at the end of the treatment, in all of the three groups studied, improvements were attained in overall asthma control and there was no statistical difference among the groups. Although there were no side effects which required the discontinuation of the treatment, it was observed that the maximum side effect was in the second group (20%, 31·6% and 20%, respectively). In conclusion, in patients who still have symptoms on treatment with inhaled corticosteroids, the addition of a long-acting β2-agonist, leukotriene antagonists or sustained-release theophylline to the treatment is a logical approach, and, in addition to inhaled corticosteroids, any one of these second controller medications may be chosen in patients with moderate asthma.</description><subject>Adrenergic beta-Agonists - therapeutic use</subject><subject>Adult</subject><subject>Anti-Asthmatic Agents - adverse effects</subject><subject>Anti-Asthmatic Agents - therapeutic use</subject><subject>Asthma - drug therapy</subject><subject>Asthma - physiopathology</subject><subject>asthma, formoterol</subject><subject>Biological and medical sciences</subject><subject>Bronchodilator Agents - therapeutic use</subject><subject>Budesonide - therapeutic use</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Drug Therapy, Combination</subject><subject>Ethanolamines - therapeutic use</subject><subject>Female</subject><subject>Formoterol Fumarate</subject><subject>Glucocorticoids - therapeutic use</subject><subject>Humans</subject><subject>Leukotriene Antagonists - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Phosphodiesterase Inhibitors - therapeutic use</subject><subject>Pneumology</subject><subject>Respiratory Mechanics - drug effects</subject><subject>Respiratory system</subject><subject>Theophylline</subject><subject>Tosyl Compounds - therapeutic use</subject><subject>treatment</subject><subject>Tropical medicine</subject><subject>zafirlukast</subject><issn>0954-6111</issn><issn>1532-3064</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMFvFCEUh4nR2LV67dFwsbdZHzAzZY7NRqtJk17qmbzCI0szM6zA1vjfC9mNnrxAXvh-v0c-xq4EbAUM6nNayG0lgNwKqeUrthGDkp2CsX_NNjANfTcKIS7Yu5yfAWDqe3jLLoQUQiktNyzt4nLAFHJcefQ8k42r4_UoKc4zJV77g8US4pp5WDk6F9rAS6zjHmdqdCrBxlwoxeAadagBWkvmv0LZ8yU6SliIYy77Bd-zNx7nTB_O9yX78fXL4-5bd_9w9313e9_ZXkDpvJcOweIAo5uGSTrwHqy3qKaRpt7rUY8SnB0BSYphGKXVT163iPWDIHXJrk-9hxR_HikXs4RsaZ5xpXjM5kZoLaUUFdyeQJtizom8OaSwYPptBJhm2TTLplk2zXINfDw3H5_ay1_8rLUCn84AZouzT7jakP9x6kYJ2bfN-sRR9fASKJlsqzhbnSeyxbgY_veHP9iQm6Y</recordid><startdate>20020501</startdate><enddate>20020501</enddate><creator>YURDAKUL, A.S.</creator><creator>ÇALIŞIR, H.C.</creator><creator>TUNÇTAN, B.</creator><creator>Ö Ǧ, M.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20020501</creationdate><title>Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma</title><author>YURDAKUL, A.S. ; ÇALIŞIR, H.C. ; TUNÇTAN, B. ; Ö Ǧ, M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c410t-ff2da0ca506d9592d0ff0cfca396e94f868620dc60ae215562c8bf8a0cacf51e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adrenergic beta-Agonists - therapeutic use</topic><topic>Adult</topic><topic>Anti-Asthmatic Agents - adverse effects</topic><topic>Anti-Asthmatic Agents - therapeutic use</topic><topic>Asthma - drug therapy</topic><topic>Asthma - physiopathology</topic><topic>asthma, formoterol</topic><topic>Biological and medical sciences</topic><topic>Bronchodilator Agents - therapeutic use</topic><topic>Budesonide - therapeutic use</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Drug Therapy, Combination</topic><topic>Ethanolamines - therapeutic use</topic><topic>Female</topic><topic>Formoterol Fumarate</topic><topic>Glucocorticoids - therapeutic use</topic><topic>Humans</topic><topic>Leukotriene Antagonists - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Phosphodiesterase Inhibitors - therapeutic use</topic><topic>Pneumology</topic><topic>Respiratory Mechanics - drug effects</topic><topic>Respiratory system</topic><topic>Theophylline</topic><topic>Tosyl Compounds - therapeutic use</topic><topic>treatment</topic><topic>Tropical medicine</topic><topic>zafirlukast</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>YURDAKUL, A.S.</creatorcontrib><creatorcontrib>ÇALIŞIR, H.C.</creatorcontrib><creatorcontrib>TUNÇTAN, B.</creatorcontrib><creatorcontrib>Ö Ǧ, M.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Respiratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>YURDAKUL, A.S.</au><au>ÇALIŞIR, H.C.</au><au>TUNÇTAN, B.</au><au>Ö Ǧ, M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma</atitle><jtitle>Respiratory medicine</jtitle><addtitle>Respir Med</addtitle><date>2002-05-01</date><risdate>2002</risdate><volume>96</volume><issue>5</issue><spage>322</spage><epage>329</epage><pages>322-329</pages><issn>0954-6111</issn><eissn>1532-3064</eissn><abstract>The objective of this study was to compare the efficacy and safety of the second controller medications (long-acting β2-agonist, leukotriene receptor antagonist and sustained-release theophylline) used in addition to inhaler corticosteroid treatment in moderate persistent asthma. A total of 64 patients with asthma, in the moderate persistent asthma category, were divided into three groups. Patients, all of whom were concurrently using inhaled corticosteroid (Budesonide 400 μ g twice daily), were treated for 3 months with either inhaled formoterol 9 μ g twice daily (first group), oral zafirlukast 20 mg twice daily (second group), or sustained-release theophylline 400 mg once daily (third group). All of the patients were subjected to assessments on the subject of peak expiratory flow (PEF) variability, forced expiratory volume in 1 sec (FEV1), asthma symptom scores (daytime and night-time), supplemental terbutalin use, asthma exacerbations and adverse events over the 3-month treatment period. In all of the three groups, significant improvements were recorded in the lung function, asthma symptom scores and supplemental terbutalin use criteria, as a result of treatments applied. Formoterol treatment resulted in significantly greater and earlier improvements compared with the other two groups in several criteria: PEF variability (17·9±2·5; 21·9±3·2; 23·7±3·3;P <0·001); asthma symptom score (daytime) (1·6±0·5; 1·9±0·5; 2·0±0,5; P<0·05); asthma symptom score (night-time) (1·2±0·4; 2·2±0·5; 1·8±0·6; P<0·001); and supplemental terbutalin use (1·2±0·3; 1·8±0·5; 1·7±0·5; P<0·05). However, at the end of the treatment, in all of the three groups studied, improvements were attained in overall asthma control and there was no statistical difference among the groups. Although there were no side effects which required the discontinuation of the treatment, it was observed that the maximum side effect was in the second group (20%, 31·6% and 20%, respectively). In conclusion, in patients who still have symptoms on treatment with inhaled corticosteroids, the addition of a long-acting β2-agonist, leukotriene antagonists or sustained-release theophylline to the treatment is a logical approach, and, in addition to inhaled corticosteroids, any one of these second controller medications may be chosen in patients with moderate asthma.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>12113382</pmid><doi>10.1053/rmed.2002.1282</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0954-6111 |
| ispartof | Respiratory medicine, 2002-05, Vol.96 (5), p.322-329 |
| issn | 0954-6111 1532-3064 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71882221 |
| source | MEDLINE; Elsevier ScienceDirect Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adrenergic beta-Agonists - therapeutic use Adult Anti-Asthmatic Agents - adverse effects Anti-Asthmatic Agents - therapeutic use Asthma - drug therapy Asthma - physiopathology asthma, formoterol Biological and medical sciences Bronchodilator Agents - therapeutic use Budesonide - therapeutic use Chronic obstructive pulmonary disease, asthma Drug Therapy, Combination Ethanolamines - therapeutic use Female Formoterol Fumarate Glucocorticoids - therapeutic use Humans Leukotriene Antagonists - therapeutic use Male Medical sciences Middle Aged Pharmacology. Drug treatments Phosphodiesterase Inhibitors - therapeutic use Pneumology Respiratory Mechanics - drug effects Respiratory system Theophylline Tosyl Compounds - therapeutic use treatment Tropical medicine zafirlukast |
| title | Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T06%3A22%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20second%20controller%20medications%20in%20addition%20to%20inhaled%20corticosteroid%20in%20patients%20with%20moderate%20asthma&rft.jtitle=Respiratory%20medicine&rft.au=YURDAKUL,%20A.S.&rft.date=2002-05-01&rft.volume=96&rft.issue=5&rft.spage=322&rft.epage=329&rft.pages=322-329&rft.issn=0954-6111&rft.eissn=1532-3064&rft_id=info:doi/10.1053/rmed.2002.1282&rft_dat=%3Cproquest_cross%3E71882221%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=71882221&rft_id=info:pmid/12113382&rft_els_id=S0954611102912825&rfr_iscdi=true |